You can directly adapt the D-MPC architecture from the paper into a “Retrosynthesis World Model + MPC Planner” for generic pharma route discovery. The key insight is:

Drug synthesis planning is not just graph search.
It is sequential decision making under uncertainty with delayed rewards and hard constraints.

That maps extremely well onto:

world models
trajectory diffusion
MPC
offline RL
multi-objective planning

The paper’s core idea of:

multi-step dynamics model
multi-step action proposal model
online planning with novel reward functions

is almost exactly what you need.

Your version becomes:

“Diffusion Model Predictive Synthesis Planning”.

Core reformulation

In D-MPC:

State = robot/environment state
Action = control action
Reward = locomotion reward

In your system:

State

current synthesis state

Action

reaction transformation

Reward

yield + cost + toxicity + manufacturability + patentability + safety + green chemistry + supply chain robustness

The planning horizon is the synthetic route.

So instead of planning robot motion trajectories, you plan synthesis trajectories.

Architecture

High level:

Input Molecule
↓
Target-conditioned route planner
↓
Diffusion action proposal model
(proposes reaction sequences)
↓
Chemical world model
(predicts outcomes/intermediates/byproducts)
↓
MPC planner / beam search / MCTS
↓
Multi-objective scorer
↓
Best synthesis route

Now let’s define each properly.

State representation

Your “state” should not just be a molecule graph.

It should be:

S_t = {
target molecule,
current intermediates,
available inventory,
reaction history,
process conditions,
toxicity profile,
cost profile,
IP proximity,
manufacturing constraints
}

Representation stack:

molecular graph embeddings
reaction graph embeddings
process graph
text embeddings from patents/papers
symbolic chemistry constraints

Use:

GNNs
graph transformers
equivariant molecular encoders
RXN embeddings
molecular fingerprints
latent process vectors

Good encoders:

ChemBERTa
MolFormer
Graphormer
GROVER
Uni-Mol
E(3)-equivariant GNNs
Action proposal model (Diffusion)

This is the equivalent of D-MPC’s action proposal diffusion model.

Instead of robot actions:

Suzuki coupling
nitration
amide coupling
hydrogenation
protecting group strategy
catalyst choice
solvent choice
temperature regime
purification step

Action space is HUGE and multimodal.
That is exactly where diffusion helps.

The paper specifically argues diffusion is good because:

trajectories are multimodal
multiple good solutions exist
long horizon dependencies matter
single-step autoregression compounds errors

That is literally synthesis chemistry.

So:
ρ(a_t:t+F | s_t)

becomes:

ρ(reaction_sequence | molecule_state)

The diffusion model proposes plausible synthetic routes.

Why diffusion instead of autoregressive transformers?
Because synthesis is:

non-local
branching
multimodal
many valid routes
highly constrained globally

Exactly like the paper’s trajectory planning argument.

Dynamics model = chemistry world model

This is the most important part.

In the paper:
p(s_{t+1:t+F} | s_t, actions)

In your case:

p(intermediates/products/byproducts/process outcomes |
current state,
reaction sequence)

This model predicts:

reaction success probability
side products
regioselectivity
stereochemistry
impurity formation
reaction yield
scalability
thermal hazards
decomposition risk
purification difficulty

This becomes a learned chemistry simulator.

Submodels inside world model

A. Forward reaction predictor
Predicts:
reactants + conditions → products

Use:

graph transformers
reaction transformers
diffusion graph models

B. Yield predictor
Predicts:

expected yield
confidence intervals

C. Toxicity model
Predict:

reagent hazards
mutagenicity
carcinogenicity
process safety
environmental toxicity

D. Manufacturability model
Predict:

scale-up feasibility
purification burden
batch robustness
sensitivity to moisture/air
process reproducibility

E. Supply chain model
Predict:

precursor availability
regional sourcing risk
lead times

F. Patentability / FTO model
Very important.

You need:

reaction novelty
route novelty
IP overlap
prior-art similarity
patent infringement risk

This is not standard retrosynthesis anymore.
This becomes strategic route generation.

Multi-objective reward function

This is where the D-MPC idea becomes extremely powerful.

The paper emphasizes runtime reward modification:
new objectives can be injected during planning.

That is perfect for pharma.

Your reward:

R =
w1 * yield

w2 * purity
w3 * cost
w4 * novelty
w5 * patentability
w6 * green chemistry
w7 * manufacturability
w8 * safety
w9 * robustness
w10 * supplier availability

Different companies can dynamically tune weights.

Example:

Generic pharma company:
optimize cost + non-infringing routes
CDMO:
optimize scalability
Discovery company:
optimize novelty
Green chemistry org:
optimize sustainability

This is a major differentiator.

Planning layer

Now you combine:

diffusion proposal model
chemistry world model
MPC planner

Exactly like D-MPC.

Planner loop:

Sample synthetic routes
Simulate outcomes
Score routes
Replan iteratively
Execute best branch

Use:

MCTS
beam search
trajectory optimization
diffusion-guided search

You can also hybridize:
Diffusion + MCTS + symbolic chemistry constraints

This is probably strongest.

Dataset strategy

This is where moat exists.

You need:

USPTO reactions
Pistachio
Reaxys
ChEMBL
PubChem
SureChEMBL
SciFinder
patent corpora
ELNs
process chemistry papers
scale-up reports

The key is:
NOT only reaction data.

You need:
process outcome data.

Especially:

failed reactions
impurity profiles
scale-up failures
safety incidents
manufacturing constraints

That data is gold.

Why world models matter here

Traditional retrosynthesis:

predicts next reaction

Your system:

imagines entire synthesis futures

This is much closer to:
“mental simulation for chemistry”.

The paper’s key advantage:
multi-step world models reduce compounding errors in long horizon planning.

That matters enormously in synthesis:
a bad protecting group decision early can destroy the route 8 steps later.

Autoregressive retrosynthesis models struggle here.

Key technical innovation opportunities

A. Latent reaction world model

Learn latent chemistry dynamics:
z_t → z_t+1

Instead of explicit molecules only.

Closer to MuZero/world models.

B. Hierarchical planning

High level:

choose synthesis strategy

Low level:

choose reactions

Like:
Strategy:

convergent synthesis
linear synthesis
biocatalytic route

Then:
specific reactions.

C. Process-aware synthesis

Most AI retrosynthesis ignores:

purification
crystallization
workup
reactor compatibility
GMP

This is where enterprise value exists.

D. Active lab loop

Closed loop:
planner → robotic lab → outcomes → retrain

This becomes self-improving chemistry intelligence.

Ultimate architecture

Long term:

Foundation Chemistry World Model

trained on:

reactions
patents
process chemistry
failures
scale-up data
toxicology
manufacturing outcomes

Then:
MPC planning over synthesis trajectories.

This becomes:
“AlphaGo for synthesis process engineering.”

Most important insight

Do NOT build:
“another retrosynthesis transformer”.

That space is crowded.

Build:
“a controllable synthesis planning world model.”

Difference:

route imagination
dynamic reward optimization
manufacturability-aware planning
patent-aware planning
process-aware planning
uncertainty-aware planning
adaptation from feedback

That is substantially more powerful.

Minimal viable v1

Build this first:

Input:
target molecule

Models:

Reaction diffusion proposal model
Forward reaction predictor
Yield predictor
Toxicity predictor
Cost estimator

Planner:
beam search + diffusion proposals

Objective:
maximize:
yield - cost - toxicity

Then expand toward:

IP
GMP
process chemistry
robotics
active learning
autonomous labs

The D-MPC paper gives you the core planning abstraction already:
learn trajectory priors + learned world model + runtime objective optimization.